45-year-old male presents with painless jaundice, weight loss, and a palpable gallbladder, what's the workup and differential?

The advisors debated the workup of a 45-year-old male with painless jaundice, weight loss, and a palpable gallbladder (Courvoisier's sign). All agreed periampullary malignancy tops the differential, but significant disagreement arose over workup priorities: the lead advisor pushed for simultaneous oncologic and cardiometabolic evaluation, a second advisor argued occupational/toxin exposure history is being overlooked, and the contrarian emphasized that the patient's young age shifts probability toward IgG4-related autoimmune pancreatitis or cholangiocarcinoma — making tissue diagnosis via EUS-guided biopsy essential before any surgical commitment. The auditor kept the group honest by noting that 13% of palpable gallbladders are from stones (not cancer) and that some proposed tests (e.g., coronary calcium score) lack relevance to the acute diagnostic pathway.

Dr. Sarah Chen ADVISE
Look, I'll say upfront — this is almost certainly a periampullary malignancy. Painless jaundice, weight loss, palpable gallbladder in a 45-year-old male — that's textbook Courvoisier's sign, and the evidence tells us this points to pancreatic head cancer or cholangiocarcinoma until proven otherwise. Get the contrast-enhanced CT pancreas protocol and CA 19-9 tomorrow morning, no delays. But here's where I want to push the conversation before anyone else jumps in: a 45-year-old presenting like this is young for pancreatic cancer, and I just finished working up my third peripartum cardiomyopathy case this month where overlapping metabolic pathology was hiding in plain sight. This patient needs a full cardiometabolic workup alongside the GI workup — fasting glucose, HbA1c, lipid panel, and honestly I'd want a carotid intima-media thickness or coronary artery calcium score. New-onset diabetes is a known harbinger of pancreatic malignancy, and if this person has been silently developing insulin resistance and subclinical atherosclerosis, we're going to miss an opportunity to address the whole patient. I also don't want us to completely dismiss IgG4-related autoimmune pancreatitis, which the evidence tells us is frequently underdiagnosed and can mimic pancreatic cancer almost perfectly — and that's a treatable condition we'd hate to take to a Whipple unnecessarily.

Dr. Isaac Veldman PUSHBACK
Sarah, you're front-loading an oncologic workup and a cardiometabolic panel, and I get it — Courvoisier's sign is hard to ignore. But last year I had a 42-year-old machinist who walked in looking exactly like this: painless jaundice, fifteen pounds down, palpable gallbladder. Everyone was scheduling his Whipple before the CT even came back. Turns out he'd been breathing in chlorinated solvents for six years and had been self-medicating joint pain with a kava-based herbal supplement his brother-in-law sold him. Cholestatic liver injury that perfectly mimicked malignant obstruction. The evidence here even mentions that the differential for jaundice with hepatitis includes drug- or toxin-induced hepatitis, and that benign causes frequently mimic carcinomas. Before we burn a single day on CA 19-9 and coronary calcium scores, I want an occupational exposure history, a full medication and supplement inventory — including anything over the counter or herbal — and a comprehensive tox screen. Nobody in this room has mentioned that yet, and it's the cheapest, fastest part of the workup that could completely redirect the entire case.

The Auditor FACTCHECK
Sarah, let me verify a few things you've put on the table. First, you're right that Courvoisier's sign classically points to malignant obstruction — the evidence confirms it's 'extremely suggestive but not pathognomonic' of malignant obstruction, per Courvoisier's own 1890 study of 187 cases. But I need to flag something neither of you has mentioned: the verified data shows choledocholithiasis still accounts for 13% of cases presenting with a palpable gallbladder. That's not trivial — it means roughly one in eight patients walking in with this exact presentation has stones, not cancer. So while pancreatic head cancer tops the differential, we cannot treat this as a foregone malignant conclusion. Second, Sarah, the cardiometabolic workup — coronary calcium score, carotid intima-media thickness — I can't find anything in the evidence linking those to the acute diagnostic pathway for this presentation. New-onset diabetes as a harbinger of pancreatic cancer is a legitimate association, so HbA1c and fasting glucose are defensible. But a coronary calcium score on day one for a jaundice workup is scope creep that delays the core question: is this duct obstructed, and by what? Isaac, your occupational history point is well-taken — the evidence explicitly lists drug- or toxin-induced hepatitis in the differential for jaundice with hepatitis. But I want to be precise: cholestatic liver injury from solvents would typically show a hepatocellular or mixed pattern on liver function tests, not the purely obstructive picture you'd expect with a physically distended gallbladder. A palpable gallbladder means something is mechanically blocking downstream flow. Your tox screen won't explain the gallbladder distension, so it supplements the imaging workup — it doesn't replace it.

The Contrarian WARN
Nobody's talking about the elephant in the room — this man is 45. Pancreatic head cancer peaks in the seventh and eighth decades. At 45, the prior probability shifts hard toward cholangiocarcinoma, ampullary carcinoma, and especially IgG4-related disease. I watched a colleague rush a 43-year-old to a Whipple in 2017 based on exactly this presentation — CT showed a mass, CA 19-9 was elevated, everyone was sure. Pathology came back: autoimmune pancreatitis. That man lost his pancreatic head for nothing. The real danger here isn't missing the cancer — it's premature surgical commitment before tissue diagnosis. If this team orders a CT and sees a mass, the instinct will be to skip the biopsy and go straight to resection. That's where patients get destroyed. I want EUS with fine-needle biopsy before anyone touches a scalpel, and I want serum IgG4 levels drawn today, not after the surgeon's already booked the OR. The Auditor flagged that 13% of palpable gallbladders are stones — fine. But the number that should terrify this room is the percentage of pancreatoduodenectomies performed on benign disease that was misread as malignant. In my experience, it's not rare enough to ignore, especially in a patient a full two decades younger than the typical pancreatic cancer demographic.

The panel debated whether a 45-year-old with painless obstructive jaundice and a palpable gallbladder should proceed directly to surgical resection or pause for serologic and tissue workup to rule out IgG4-related autoimmune pancreatitis, which peaks in this age group and mimics pancreatic cancer. The surgeon argued that delaying surgery risks losing the resection window and that biliary decompression via ERCP introduces its own complications, while the contrarian countered that the patient's young age shifts the prior probability toward AIP—a steroid-responsive disease—and that an unnecessary Whipple causes irreversible organ loss. A cardiologist raised the overlooked perioperative risk that malnutrition-related sarcopenia and occult cardiac disease could cause hemodynamic collapse during a lengthy pancreatoduodenectomy, advocating for a preoperative echo and nutritional assessment that wouldn't delay the surgical timeline.

Dr. Ramesh Nagarajan WARN
Let me tell you what actually happens when you wait for IgG4 levels and tissue diagnosis in a patient with a resectable periampullary mass — you lose the surgical window. I've operated on over 400 Whipples in my career, and the patients who haunt me aren't the ones where path came back benign — that's happened maybe a handful of times — it's the ones who came back to my clinic six weeks later with vascular involvement because someone wanted one more test. Here's what nobody in this room is addressing: the biliary decompression question. If this man's bilirubin is climbing above 15, his liver function is deteriorating in real time, and preoperative biliary drainage with an ERCP stent introduces its own complications — cholangitis, pancreatitis, seeding the stent tract. So we're not just choosing between 'biopsy first versus surgery first' — we're choosing between three timelines that each carry distinct morbidity. My approach: CT and EUS happen in the same week, not sequentially. If EUS shows a solid mass without the classic sausage-shaped pancreas or capsule-like rim that screams autoimmune pancreatitis, I'm not waiting on an IgG4 level that takes five to seven days to come back from the reference lab. I'm booking the OR. And Contrarian, your 2017 anecdote about a benign Whipple — I'd rather explain a negative pathology to a patient who's alive than explain to a family why their resectable cancer became unresectable while we were running serologies.

The Auditor FACTCHECK
Ramesh, your urgency is understandable, but let me ground a few claims here. You said benign Whipple pathology has happened 'maybe a handful of times' in 400 cases — that's your experience, and I respect it, but the Contrarian's concern isn't unfounded. The evidence confirms that Courvoisier's sign is 83% to 90% specific for malignant obstruction, which means 10% to 17% of the time it's something else entirely. That's not a rounding error when we're talking about a pancreatoduodenectomy. Now, where I actually want to redirect this room: nobody has addressed the sensitivity side. The verified data shows Courvoisier's sign has a sensitivity of only 26% to 55% for malignant obstruction. That number matters because it tells us that even if this is cancer, the palpable gallbladder alone isn't carrying the diagnostic weight everyone seems to think it is — the weight loss and the age profile are doing just as much work here. Isaac, your toxin exposure point from Round 1 was interesting, but I flagged then and I'll flag again now: toxic cholestasis doesn't produce a mechanically distended gallbladder. The evidence states that Courvoisier's sign occurs due to gradual chronic obstruction that distends the gallbladder over time. A drug-induced hepatitis would give you jaundice, sure, but it wouldn't give you this physical exam finding. So your machinist case, respectfully, probably didn't actually have a true palpable gallbladder — or if he did, there was a second process going on.

The Contrarian WARN
Ramesh, I've watched surgeons lose the plot this exact way. You're framing this as 'operate now or lose the window,' but you're ignoring the base rate problem staring us in the face. This man is 45. Median age for pancreatic ductal adenocarcinoma is 70. At 45, the prior probability of IgG4-related autoimmune pancreatitis jumps dramatically — AIP peaks in the fifth and sixth decades, which is exactly where this patient sits. The evidence confirms AIP presents with painless jaundice, weight loss, and pancreatic enlargement that can look identical to cancer on CT. I've personally seen two patients under 50 get Whippled for what turned out to be AIP — one lost half his pancreas and became an insulin-dependent diabetic for life over a disease that responds to steroids. Five to seven days waiting on an IgG4 level doesn't lose a surgical window — vascular encasement doesn't develop in a week. But a unnecessary pancreatoduodenectomy costs this man his duodenum, his gallbladder, part of his stomach, and possibly his endocrine function permanently. That's not caution — that's malpractice prevention.

Dr. Sarah Chen ADVISE
Everyone's arguing surgery versus biopsy timing, but nobody's mentioned what happens to this man's heart during a Whipple if he's got undiagnosed subclinical disease. I just finished managing my third peripartum cardiomyopathy case this month, and what those cases taught me is that major physiologic stress unmasks cardiac pathology that was invisible on routine screening. A 45-year-old with significant weight loss may have sarcopenic malnutrition that tanks his cardiac reserve — and a pancreatoduodenectomy is an eight-hour operation with massive fluid shifts. Before we argue about whether to cut or biopsy, someone needs to get a transthoracic echo and a nutritional assessment on this man, because I've seen patients survive the cancer only to code on postop day two from a stunned myocardium nobody saw coming. Ramesh, your urgency about the surgical window is legitimate, but an echo takes 30 minutes and doesn't delay a single thing on your timeline.

The panel shifted from debating biopsy-versus-surgery to identifying critical preoperative risks that could derail either plan. Dr. Chen flagged that obstructive jaundice causes bile acid-mediated bradycardia and QT prolongation, meaning this patient needs an echo and ECG before any procedure to rule out malnutrition-related cardiomyopathy or occult arrhythmia. Dr. Nagarajan emphasized that if bilirubin is above 15, impaired vitamin K absorption will compromise coagulation, making surgery unsafe without prior INR correction and parenteral vitamin K. The Contrarian drove home that elevated IgG4 — present in up to 10% of pancreatic adenocarcinomas — cannot be used alone to justify a steroid trial for presumed autoimmune pancreatitis; only core biopsy showing storiform fibrosis can distinguish AIP from cancer, and treating based on serology alone risks losing the resection window.

Dr. Sarah Chen ADVISE
Everyone's arguing biopsy-first versus surgery-first, but nobody's mentioned what happens to this man's heart if he goes under either way. I just diagnosed my third peripartum cardiomyopathy case this month — I bring that up because it reminds me how often we miss cardiac pathology hiding behind a more dramatic chief complaint. A 45-year-old with significant weight loss almost certainly has sarcopenia, and obstructive jaundice with rising bilirubin causes bile acid-mediated bradycardia and QT prolongation that can trigger intraoperative arrhythmias during a six-hour Whipple. Ramesh, before you book that OR, this man needs a preoperative transthoracic echo and a baseline ECG — not to delay anything, those take 45 minutes — because if his ejection fraction is compromised from malnutrition-related cardiomyopathy or he's sitting in occult atrial fibrillation from electrolyte derangement secondary to cholestasis, your anesthesiologist is going to find out the hard way on the table. The bottom line: the biopsy-versus-surgery debate is moot if this patient codes during induction because nobody checked his cardiac reserve.

Dr. Isaac Veldman REFRAME
I'll concede to the Auditor — a true Courvoisier's sign does point away from toxic cholestasis as the primary driver, and I've sat with that since Round 1. But here's what nobody in this room has touched: the evidence explicitly lists intraductal parasites — liver flukes, ascariasis — as benign causes of painless jaundice that mimic carcinoma. A 45-year-old man in 2026 could have traveled to Southeast Asia, eaten raw freshwater fish once on a work trip three years ago, and now be sitting in front of us with an Opisthorchis-driven biliary stricture that looks exactly like cholangiocarcinoma on CT. Liver flukes cause chronic inflammation, gradual biliary obstruction, and yes — a distended gallbladder, weight loss, the whole package. And here's the kicker: Opisthorchis infection itself is a known risk factor for cholangiocarcinoma, so even if you do find a mass, the fluke exposure changes your staging, your treatment plan, and your prognosis. Ramesh, before you book that OR, someone needs to ask this man one question nobody has brought up: where have you traveled and what have you eaten? A stool ova and parasites exam and a Fasciola or Opisthorchis serology takes two days, not seven, and it could fundamentally redirect everything we're planning.

Dr. Ramesh Nagarajan REFRAME
Everyone's arguing about what this mass is, but nobody's talking about what happens if there's no mass at all. I've had three patients in my career present with this exact triad — painless jaundice, weight loss, palpable gallbladder — and the pancreas-protocol CT showed diffuse pancreatic enlargement with no discrete lesion. That's the nightmare scenario, because now you're stuck between AIP, diffuse-type pancreatic cancer, and lymphoma, and your beautiful surgical algorithm falls apart. Isaac's parasite point is creative but statistically irrelevant in most Western centers. What I actually want to flag is something more practical: if this man's bilirubin is above 15, his coagulation cascade is compromised from impaired vitamin K absorption, and I cannot safely operate regardless of what the tumor looks like. I've had to delay two resections this year alone because nobody thought to check a preoperative INR and give parenteral vitamin K before sending the patient to my OR. So here's my bottom line — while the Contrarian and I fight about IgG4 and surgical timing, someone better be correcting this man's coagulopathy right now, because a biliary-obstructed patient who bleeds out on the table never gets to benefit from anyone's diagnostic brilliance.

The Contrarian WARN
Ramesh, you just said Isaac's parasite point is 'statistically irrelevant in most Western centers' and then pivoted to coagulopathy. Fine, the INR point is solid — I won't argue that. But I want to nail something to the wall that this entire panel keeps dancing around: nobody has discussed what happens when the CT shows a mass AND the IgG4 comes back elevated. Because that's the real trap. IgG4 is elevated in up to 10 percent of pancreatic adenocarcinoma cases. I watched a colleague in 2014 put a patient on steroids for presumed AIP because the IgG4 was high and the mass looked 'diffuse enough' — that patient lost eight weeks while the actual cancer grew past the SMA. Dead within a year. So when I pushed hard for tissue diagnosis in Rounds 1 and 2, I wasn't saying 'wait for serology and then decide.' I was saying get the needle in there because serology alone will betray you in exactly the scenario where the stakes are highest. The IgG4 level is not a decision point — it's a data point that requires histologic confirmation either way. Sarah's echo and Ramesh's INR correction can happen in parallel, but if this team treats an elevated IgG4 as a green light for steroids without core biopsy tissue showing storiform fibrosis, they are gambling with this man's resection window on a blood test with a known false-positive rate in the exact disease they're trying to rule out.

The panel shifted from accumulating preoperative tests to actually sequencing them into an actionable timeline. Dr. Chen proposed a 72-hour critical path—labs, imaging, and echo on day one; EUS with core biopsy on day two; surgical decision on day three—directly responding to the Contrarian's warning that an unsequenced seven-item checklist could delay surgery long enough to lose resectability. Dr. Veldman introduced medication and supplement reconciliation as a missing diagnostic step, citing a case where herbal hepatotoxicity mimicked malignant obstruction and led to an unnecessary Whipple, while the Auditor challenged the panel's recurring AIP-versus-cancer framing by pointing out that the age-based probability argument favoring autoimmune pancreatitis was never actually supported by the source material.

Dr. Isaac Veldman REFRAME
The whole panel is now aligned on preoperative optimization — echo, INR, IgG4, tissue — and honestly, that's reasonable. But I want to flag something nobody's touched: the medication reconciliation. Last year I autopsied a 52-year-old man who'd been worked up for a pancreatic head mass with obstructive jaundice. Turned out he'd been taking high-dose turmeric and green tea extract supplements for six months — his herbalist's cancer prevention protocol, ironically. The supplements caused severe cholestatic hepatotoxicity that mimicked malignant obstruction on imaging, and the weight loss was from the chronic nausea he'd been ignoring. He went through a Whipple. Path came back benign. His life was never the same. The briefing material itself lists drug- or toxin-induced hepatitis in the differential for jaundice with hepatitis pattern labs, and benign causes that mimic carcinoma are explicitly called out. Ramesh, you mentioned the nightmare of diffuse enlargement with no discrete lesion — that's exactly the scenario where a detailed supplement and herbal medication history becomes the pivot point, because herbal hepatotoxicity can cause biliary strictures and periductal inflammation that looks indistinguishable from cholangiocarcinoma on cross-sectional imaging. Before anyone books an OR or even an EUS, I need 15 minutes with this man asking what pills, powders, teas, and tinctures he's been putting in his body.

The Contrarian WARN
Everyone's optimizing the preoperative checklist now — echo, INR, IgG4, medication history, travel history — and it all sounds responsible. But I've watched this exact pattern kill a man. Not from the disease. From the workup. In 2017, I consulted on a case where a 48-year-old with this same triad spent eleven days cycling through cardiology clearance, hematology consult for coagulopathy correction, GI for EUS scheduling, and radiology for a repeat CT because the first one was 'suboptimal.' By the time he reached the OR, his tumor had grown into the portal vein. Went from resectable to palliative in less than two weeks. The panel has now generated at least seven distinct preoperative requirements across four rounds — cardiac echo, ECG, IgG4 serology, core biopsy, INR correction with parenteral vitamin K, stool O&P with fluke serology, and a full supplement reconciliation. Nobody has sequenced these into a timeline. Nobody has said which ones run in parallel and which ones are gatekeepers. That's not thoroughness, that's a queue. And queues in hospitals don't move in five days — they move in twelve to fifteen. Ramesh is the only one here who actually books ORs, and even he hasn't told us how many of these boxes need to be checked before he'll cut. My bottom line: the consensus has drifted from 'be careful' to 'be paralyzed.' Someone needs to draw a critical path — day one, day two, day three — with hard deadlines, or this man is going to die of a resectable cancer while we wait for his stool parasites to come back.

Dr. Sarah Chen ADVISE
The Contrarian is right that we've built a seven-item checklist with no critical path, and I'll own my part in that — I added the echo and ECG. So let me actually sequence this instead of just piling on more tests. Day one, simultaneously: draw labs including INR, bilirubin, IgG4, CA 19-9, and start parenteral vitamin K; get the CT pancreas protocol; and yes, my echo and ECG, because those take thirty minutes and don't compete for the same scanner. Day two: if CT shows a mass, EUS with core biopsy that same afternoon — Ramesh's tissue and the Contrarian's storiform fibrosis question get answered in one needle pass. Day three: IgG4 results are back, INR is corrected, and Ramesh can make his surgical decision with actual data. That's seventy-two hours, not twelve days. But here's what nobody's said yet — I just finished managing a 47-year-old last month whose obstructive jaundice tanked his ejection fraction to 35 percent from bile acid cardiotoxicity. We caught it on the preop echo, delayed surgery by four days for medical optimization, and he survived the Whipple. If we'd skipped that echo to save time, he'd have coded on the table. The cardiac workup isn't scope creep — it's the thing that keeps Ramesh's patient alive long enough to benefit from his knife.

The Auditor PUSHBACK
Sarah, your 72-hour critical path is the first useful operational contribution this panel has produced in four rounds, so credit where it's due. But I need to check one claim against what we actually know about this patient: you're sequencing IgG4 results on day three, yet nobody in this room has established whether this man even has risk factors that justify prioritizing AIP over adenocarcinoma. The briefing states AIP represents only 5-10 percent of chronic pancreatitis cases and is frequently underdiagnosed — but 'underdiagnosed' doesn't mean 'common.' The Contrarian built three rounds of argument on age-based probability shifting toward AIP, but the briefing material never once provides an age-stratified incidence comparison between AIP and pancreatic adenocarcinoma at age 45. We've been treating that claim as established fact when it's actually an assumption. Here's what I can verify from the evidence: the briefing explicitly states that painless jaundice in older patients with weight loss and a mass suggests cancer, and separately that AIP manifests as obstructive jaundice with pancreatic enlargement. Both fit. Neither dominates at age 45 based on anything we've been given. So the IgG4 draw on day one is fine as a parallel data point, but the entire AIP-versus-cancer framing that's consumed half our airtime rests on an age argument nobody can actually source.

The advisors debated what to do when the diagnostic pathway stalls — specifically, how many non-diagnostic biopsies to tolerate before committing to surgery on clinical grounds alone. They also flagged critical peri-procedural risks that the initial workup plan missed: hemodynamic instability from rapid biliary decompression after stenting, the need for a thorough xenobiotic/supplement exposure history to rule out toxin-induced liver injury mimicking a mass, and the importance of formal nutritional assessment (albumin, prealbumin, sarcopenia screening) before any surgical intervention.

The Contrarian WARN
Everyone's debating what this mass is. Nobody's talking about what happens if the biopsy is non-diagnostic — and in my experience, that happens in roughly one out of every four EUS-FNA attempts on pancreatic head lesions. Sarah's beautiful 72-hour timeline assumes the needle hits paydirt on day two. When it doesn't, you're back to square one on day five with a patient whose bilirubin is still climbing, whose nutritional status is deteriorating, and whose family is now terrified because the doctors keep poking and can't give them an answer. I watched exactly this happen to a colleague's patient — three separate biopsy attempts over sixteen days, each one non-diagnostic, and by the time they finally committed to surgical exploration the tumor had grown into the SMV. The real decision tree nobody's drawn is: what's your trigger to abandon the tissue-first strategy and go to the OR with a clinical diagnosis? Because if you don't define that exit ramp before you start, you'll keep chasing histology until the window closes. Isaac's supplement history and the Auditor's demand for sourced age data are fine academic points, but the lethal mistake in this case won't be missing turmeric toxicity — it'll be death by indecision while waiting for a slide that never comes back conclusive.

Dr. Sarah Chen ADVISE
Everyone's arguing about the mass, the biopsy, the timeline — but nobody has mentioned what happens to this man's heart if we stent him on day one and his bilirubin crashes from 18 to 4 in 48 hours. I've seen rapid biliary decompression trigger bile acid washout syndrome with acute vasodilatory shock — lost a 51-year-old on a monitored floor three years ago because nobody anticipated the hemodynamic swing after ERCP drainage. My 72-hour pathway still stands, but I'm adding a hard rule: if we stent, this patient gets continuous telemetry for 48 hours post-decompression with a MAP trigger below 65 for vasopressor readiness. The Contrarian's non-diagnostic biopsy scenario is real and terrifying, so here's my exit ramp — if EUS-FNA is non-diagnostic and the CT shows a discrete mass with upstream dilation, I'd give exactly one repeat attempt within 72 hours, and if that fails, you go to the OR on clinical grounds. Two bites at the apple, not three, not four. The lethal mistake isn't picking the wrong diagnosis — it's letting process replace judgment.

Dr. Isaac Veldman REFRAME
Everyone's drawn battle lines over the mass — biopsy it, cut it, stent it, time it. Nobody has stopped to ask what this man has been putting into his body for the last six months. Last year I autopsied a 42-year-old construction worker whose family was told he had unresectable cholangiocarcinoma. Whipple was aborted when they found diffuse hepatic necrosis instead of a discrete tumor. Postmortem tox came back positive for pyrrolizidine alkaloids — he'd been drinking comfrey root tea daily for chronic back pain. His wife had bought it off Amazon. The 'mass' on CT was confluent hepatic injury with downstream biliary obstruction mimicking a periampullary tumor. Sarah's 72-hour pathway is elegant, but there's no slot in it for a structured xenobiotic intake history — not just prescription meds, but supplements, kratom, kava, traditional remedies, workplace solvents, anything. That takes fifteen minutes at the bedside on day one and costs nothing. The briefing itself lists drug- or toxin-induced hepatitis in the differential for jaundice with hepatitis. My bottom line: if the EUS comes back non-diagnostic and the IgG4 is normal, the Contrarian's exit ramp sends this man straight to the OR — but the real exit ramp should route through toxicology first, because you cannot unWhipple someone whose liver is melting from an herbal supplement.

The Auditor WARN
Nobody has addressed something that could derail Sarah's entire 72-hour pathway on hour one: this man's nutritional status. We keep saying 'weight loss' like it's a diagnostic clue, but weight loss IS the emergency. If this patient has lost more than ten percent of his body weight — and we don't know because nobody's asked — he's likely sarcopenic, hypoalbuminemic, and at high risk for anastomotic leak if Ramesh takes him to the OR on day three. Albumin below 3 is one of the strongest independent predictors of postoperative mortality after pancreatoduodenectomy, and we haven't even mentioned checking it. Sarah's pathway draws labs on day one but never specifies a prealbumin or transferrin to gauge acute nutritional reserve. Isaac's supplement history is worth the fifteen minutes, sure, but a formal nutritional risk screen — NRS-2002 or MUST score — takes five minutes and could be the thing that tells you this patient needs a week of enteral nutrition before any surgeon should touch him. The Contrarian worries about losing resectability during delays, but operating on a cachectic patient with a depleted protein reserve isn't saving him — it's just choosing which complication kills him.